{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:51:11Z","timestamp":1792047071767,"version":"4.4.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transfused platelets (plts) are either pooled random-donor platelet (plt) concentrates or single-donor apheresis plts. When stored for 5 days, all of these products are equally efficacious.<\/jats:p><jats:p>A 10,000\/\u03bcL prophylactic plt transfusion trigger has been documented to be both hemostatically efficacious and cost effective in reducing plt transfusion requirements. The optimal plt dose\/transfusion is being evaluated in an ongoing clinical trial. Therapeutic plt transfusions to control or prevent bleeding with trauma or surgical procedures require higher transfusion triggers of 100,000\/\u03bcL for neurosurgical procedures and between 50,000\/\u03bcL and 100,000\/\u03bcL for other invasive procedures or trauma.<\/jats:p><jats:p>Leukoreduction has been documented to reduce plt alloimmunization rates, cytomegalovirus (CMV) transmission by transfusion, and febrile transfusion reactions. Whether it reduces immunomodulatory effects of transfusion (i.e., decreases infection rates and cancer recurrence) is still controversial, as is universal leukoreduction.<\/jats:p><jats:p>Poor responses to plt transfusions are often multifactorial. For alloimmune plt refractoriness, HLA matching, cross-matching, and identification of the specificity of the patient\u2019s antibodies with avoidance of mismatched donor antigens are all equally effective in identifying compatible plts for transfusion. Other causes of poor plt responses are splenomegaly, ABO mismatching, females with 2 or more pregnancies and males, use of heparin or amphotericin, bleeding, fever, graft-vs-host disease (GVHD), and vaso-occlusive disease (VOD).<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.172","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T18:08:40Z","timestamp":1195236520000},"page":"172-178","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":191,"title":["Evidence-Based Platelet Transfusion Guidelines"],"prefix":"10.1182","volume":"2007","author":[{"given":"Sherrill J.","family":"Slichter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703234667500_R1","doi-asserted-by":"crossref","unstructured":"Slichter SJ, Harker LA. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. Br J Haematol. 1976;34:395\u2013402.","DOI":"10.1111\/j.1365-2141.1976.tb03586.x"},{"key":"2019111703234667500_R2","unstructured":"Pietersz RNI, Loos JA, Reesink HW. Platelet concentrates stored in plasma for 72 hours at 22\u00b0C prepared from buffy coats of citrate-phosphate-dextrose blood collected in a quadruple-bag saline-adenine-glucose-mannitol system. Vox Sang. 1985;49:81\u201385."},{"key":"2019111703234667500_R3","doi-asserted-by":"crossref","unstructured":"Keegan T, Heaton A, Holme S, et al. Paired comparison of platelet concentrates prepared from platelet-rich plasma and buffy coats using a new technique with 111In and 51Cr. Transfusion. 1992;32:113\u2013120.","DOI":"10.1046\/j.1537-2995.1992.32292180138.x"},{"key":"2019111703234667500_R4","doi-asserted-by":"crossref","unstructured":"Cardigan R, Williamson LM. The quality of platelets after storage for 7 days. Transfus Med. 2003;13:173\u2013187.","DOI":"10.1046\/j.1365-3148.2003.00449.x"},{"key":"2019111703234667500_R5","doi-asserted-by":"crossref","unstructured":"Bertolini F, Rebulla P, Riccardi D, et al. Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion. 1989;29:605\u2013609.","DOI":"10.1046\/j.1537-2995.1989.29789369678.x"},{"key":"2019111703234667500_R6","unstructured":"Slichter SJ, Jones MK, Christoffel T, et al. Long-term platelet storage: in vivo platelet viability maintained for 8 days in plasma and 13 days in Plasmalyte [abstract]. Blood. 2003;102:93a."},{"key":"2019111703234667500_R7","doi-asserted-by":"crossref","unstructured":"Slichter SJ, Bolgiano D, Corson J, et al. In vivo evaluation of extended stored platelet concentrates [abstract]. Blood. 2006;108:282a\u2013283a.","DOI":"10.1182\/blood.V108.11.946.946"},{"key":"2019111703234667500_R8","doi-asserted-by":"crossref","unstructured":"Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The retrovirus epidemiology donor study. N Engl J Med. 1996;334:1685\u20131690.","DOI":"10.1056\/NEJM199606273342601"},{"key":"2019111703234667500_R9","doi-asserted-by":"crossref","unstructured":"Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion. 2001;41:857\u2013861.","DOI":"10.1046\/j.1537-2995.2001.41070857.x"},{"key":"2019111703234667500_R10","unstructured":"Fridey JL, ed. Standards for Blood Banks and Transfusion Services, 22nd Ed. Bethesda, MD: American Association of Blood Banks; 2003:13."},{"key":"2019111703234667500_R11","doi-asserted-by":"crossref","unstructured":"The Trial To Reduce Alloimmunization To Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861\u20131869.","DOI":"10.1056\/NEJM199712253372601"},{"key":"2019111703234667500_R12","doi-asserted-by":"crossref","unstructured":"Chambers LA, Herman JH. Considerations in the selection of a platelet component: apheresis versus whole blood-derived. Transfus Med Rev. 1999;13:311\u2013322.","DOI":"10.1016\/S0887-7963(99)80060-1"},{"key":"2019111703234667500_R13","doi-asserted-by":"crossref","unstructured":"Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005;19:181\u2013199.","DOI":"10.1016\/j.tmrv.2005.02.002"},{"key":"2019111703234667500_R14","doi-asserted-by":"crossref","unstructured":"Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion. 2002;42:556\u2013566.","DOI":"10.1046\/j.1537-2995.2002.00094.x"},{"key":"2019111703234667500_R15","doi-asserted-by":"crossref","unstructured":"Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 2001;97:1180\u20131195.","DOI":"10.1182\/blood.V97.5.1180"},{"key":"2019111703234667500_R16","doi-asserted-by":"crossref","unstructured":"Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion. 2001;41:691\u2013712.","DOI":"10.1046\/j.1537-2995.2001.41050691.x"},{"key":"2019111703234667500_R17","doi-asserted-by":"crossref","unstructured":"Leitman SF. Use of blood cell irradiation in the prevention of posttransfusion graft-versus-host disease. Transfus Sci. 1989;10:219\u2013232.","DOI":"10.1016\/0955-3886(89)90029-5"},{"key":"2019111703234667500_R18","doi-asserted-by":"crossref","unstructured":"Schoenfeld H, Muhm M, Doepfmer UR, et al. The functional integrity of platelets in volume-reduced platelet concentrates. Anesth Analg. 2005;100:78\u201381.","DOI":"10.1213\/01.ANE.0000140239.43116.30"},{"key":"2019111703234667500_R19","doi-asserted-by":"crossref","unstructured":"Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Trans Med Rev. 2004;18:153\u2013167.","DOI":"10.1016\/j.tmrv.2004.03.003"},{"key":"2019111703234667500_R20","doi-asserted-by":"crossref","unstructured":"Wandt H, Schaefer-Eckart K, Frank M, et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37:387\u2013392.","DOI":"10.1038\/sj.bmt.1705246"},{"key":"2019111703234667500_R21","doi-asserted-by":"crossref","unstructured":"Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol. 1978;7:523\u2013539.","DOI":"10.1016\/S0308-2261(21)00047-3"},{"key":"2019111703234667500_R22","doi-asserted-by":"crossref","unstructured":"Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905\u2013909.","DOI":"10.1056\/NEJM196205032661802"},{"key":"2019111703234667500_R23","unstructured":"Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;56:1105\u20131109."},{"key":"2019111703234667500_R24","doi-asserted-by":"crossref","unstructured":"Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519\u20131538.","DOI":"10.1200\/JCO.2001.19.5.1519"},{"key":"2019111703234667500_R25","doi-asserted-by":"crossref","unstructured":"British Committee for Standards in Haematology, Blood Transfusion Task Force (Chairman P Kelsey). Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10\u201323.","DOI":"10.1046\/j.1365-2141.2003.04468.x"},{"key":"2019111703234667500_R26","doi-asserted-by":"crossref","unstructured":"Tinmouth AT, Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus Med Rev. 2003;17:181\u2013193.","DOI":"10.1016\/S0887-7963(03)00018-X"},{"key":"2019111703234667500_R27","doi-asserted-by":"crossref","unstructured":"Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apheresis. 2006;21:78\u201384.","DOI":"10.1002\/jca.20090"},{"key":"2019111703234667500_R28","doi-asserted-by":"crossref","unstructured":"Folman CC, de Jong SM, de Haas M, et al. Analysis of the kinetics of TPO uptake during platelet transfusion. Transfusion. 2001;41:517\u2013521.","DOI":"10.1046\/j.1537-2995.2001.41040517.x"},{"key":"2019111703234667500_R29","doi-asserted-by":"crossref","unstructured":"Heddle NM, Cook RJ, Sigouin C, et al. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion. 2006;46:903\u2013911.","DOI":"10.1111\/j.1537-2995.2006.00822.x"},{"key":"2019111703234667500_R30","unstructured":"Slichter SJ, Murphy S, Buchholz D, et al. INTERCEPT platelets and conventional platelets provide comparable hemostatic responses in thrombocytopenic patients: the SPRINT trial [abstract]. Blood. 2002;100:141b."},{"key":"2019111703234667500_R31","doi-asserted-by":"crossref","unstructured":"Wall MH, Prielipp RC. Transfusion in the operating room and the intensive care unit: current practice and future directions. Int Anesthesiol Clin. 2000;38:149\u2013169.","DOI":"10.1097\/00004311-200010000-00011"},{"key":"2019111703234667500_R32","doi-asserted-by":"crossref","unstructured":"Slichter SJ, Davis K, Enright H, et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106\u20134114.","DOI":"10.1182\/blood-2003-08-2724"},{"key":"2019111703234667500_R33","doi-asserted-by":"crossref","unstructured":"Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood. 1965;26:732\u2013743.","DOI":"10.1182\/blood.V26.6.732.732"},{"key":"2019111703234667500_R34","doi-asserted-by":"crossref","unstructured":"Carr R, Hutton JL, Jenkins JA, et al. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol. 1990;75:408\u2013413.","DOI":"10.1111\/j.1365-2141.1990.tb04356.x"},{"key":"2019111703234667500_R35","doi-asserted-by":"crossref","unstructured":"Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev. 1998;12:258\u2013270.","DOI":"10.1016\/S0887-7963(98)80002-3"},{"key":"2019111703234667500_R36","doi-asserted-by":"crossref","unstructured":"Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev. 2000;14:180\u2013196.","DOI":"10.1016\/S0887-7963(00)80007-3"},{"key":"2019111703234667500_R37","doi-asserted-by":"crossref","unstructured":"Slichter SJ. Understanding the effects of different types of white cells on patient\u2019s responses to transfusion: immunization versus tolerization. Vox Sang. 2002;83:421\u2013424.","DOI":"10.1111\/j.1423-0410.2002.tb05345.x"},{"key":"2019111703234667500_R38","doi-asserted-by":"crossref","unstructured":"Sowemimo-Coker SO, Kim A, Tribble E, et al. White cell subsets in apheresis and filtered platelet concentrates. Transfusion. 1998;38:650\u2013657.","DOI":"10.1046\/j.1537-2995.1998.38798346633.x"},{"key":"2019111703234667500_R39","doi-asserted-by":"crossref","unstructured":"Ishida A, Handa M, Wakui M, et al. Clinical factors influencing posttransfusion platelet increments in patients undergoing hematopoietic progenitor cell transplantation: a prospective analysis. Transfusion. 1998;38:839\u2013847.","DOI":"10.1046\/j.1537-2995.1998.38998409004.x"},{"key":"2019111703234667500_R40","doi-asserted-by":"crossref","unstructured":"Vidarsson B, Ondundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost. 2000;83:634\u2013635.","DOI":"10.1055\/s-0037-1613879"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/172\/646281\/172_178ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/172\/646281\/172_178ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T01:53:25Z","timestamp":1630115605000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/172\/19196\/EvidenceBased-Platelet-Transfusion-Guidelines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.172","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}